# IMPACT: A Study to Explore the Efficacy and Safety of Paliperidone ER in Patients With Acute Agitation

> **NCT01050478** · PHASE4 · COMPLETED · sponsor: **Janssen Cilag N.V./S.A.** · enrollment: 56 (actual)

## Conditions studied

- Psychomotor Agitation
- Acute Disease

## Interventions

- **DRUG:** Paliperidone ER
- **DRUG:** Benzodiazepine

## Key facts

- **NCT ID:** NCT01050478
- **Lead sponsor:** Janssen Cilag N.V./S.A.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-03
- **Primary completion:** 2011-12
- **Final completion:** 2011-12
- **Target enrollment:** 56 (ACTUAL)
- **Last updated:** 2016-02-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01050478

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01050478, "IMPACT: A Study to Explore the Efficacy and Safety of Paliperidone ER in Patients With Acute Agitation". Retrieved via AI Analytics 2026-06-15 from https://api.ai-analytics.org/clinical/NCT01050478. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*